Table 3.
Health state utility values by treatment line, health state and instrument
| Study | Health state | Utility valuea | Instrument | Tariff | Respondent details | HTA suitability |
|---|---|---|---|---|---|---|
| 1st line | ||||||
| Nafees 2016 [68] Metastatic NSCLCb |
PD vs BL state | 0.095 | TTO | N/A | Patients (but not NSCLC patients) from the general public in UK, Australia, France, China, S. Korea, Taiwan | No |
| RES no side effects vs BL | 0.773 | |||||
| SDis no side effects vs BL | 0.460 | |||||
| Chevalier 2013c [38] Advanced/metastatic NSCLC |
1 L PF | 0.69 (0.26) | EQ-5D | French (TTO) | Stage I–Stage III/IV PF and PD | Meets HAS requirements |
| 1 L PD | 0.61 (0.24) | |||||
| Chouaid 2013 [39] Advanced/metastatic NSCLC |
1 L PF | 0.71 (0.24) (95% CI, 0.67–0.76) | EQ-5D-3 L | UK | At time of advanced diagnosis, mean age 64.8 years Adenocarcinoma: 65.2% Large-cell carcinoma: 6.8% SQ cell carcinoma: 17.1% Other: 9.9% Clinical stage at time of survey: IIIb: 17.9% IV: 82.1% |
Meets NICE requirements |
| 69.31 (18.33) (95% CI, 65.9–72.8) | EQ-5D VAS | N/A | No | |||
| 1 L PD | 0.67 (0.2) (95% CI 0.59–0.75) | EQ-5D-3 L | UK | Meets NICE requirements | ||
| 58.67 (17.4) (95% CI 51.3–66.0) | EQ-5D VAS | N/A | No | |||
| Iyer 2013 [46] Advanced/metastatic NSCLC |
France, Germany 1 L | 0.63 (0.31) | EQ-5D | UK1 | Patients with: Adenocarcinoma: 56.3% Large-cell carcinoma: 11.8% SQ cell carcinoma: 29.3% Other: 2.5% Stage IIIb: 15.4% Stage: IV 84.6% |
Meets NICE requirement |
| 60.8 (19.9) | EQ-5D VAS | N/A | No | |||
| ≥ 1st line | ||||||
| Iyer 2013 [46] Advanced/metastatic NSCLC |
France, Germany 1 L/2 L | 0.58 (0.35) | EQ-5D | UK | Patients with: Adenocarcinoma: 56.3% Large-cell carcinoma: 11.8% SQ cell carcinoma: 29.3% Other: 2.5% Stage IIIb: 15.4% Stage: IV 84.6% |
Meets NICE and SMC requirements |
| France, 1 L/2 L | 0.57 (0.41) | |||||
| Germany, 1 L/2 L | 0.59 (0.31) | |||||
| France, Germany 1 L/2 L | 58.0 (19.9) | EQ-5D VAS | No | |||
| France, 1 L/2 L | 57.1 (21.1) | |||||
| Germany, 1 L/2 L | 58.6 (19.1) | |||||
| 2nd line | ||||||
| Blackhall 2014 [41] Advanced/metastatic ALK+ NSCLC |
2 L BL CRZ | 0.73 (0.24) | EQ-5D-3 L | NR | Multinational patients, locally advanced/metastatic ALK+ NSCLC, 2 L | Unclear as tariff NR |
| 2 L BL chemotherapy (PEM or DOC) | 0.70 (0.26) | |||||
| 2 L BL PEM | 0.73 (0.24) | |||||
| 2 L BL DOC | 0.67 (0.29) | |||||
| 2 L on CRZ | 0.82 (SE, 0.01) (95% CI, 0.79–0.85) |
|||||
| 2 L on Chemotherapy | 0.73 (SE, 0.02) (95% CI, 0.70–0.77) |
|||||
| 2 L on PEM | 0.74 (SE, 0.02) (95% CI, 0.70–0.79) |
|||||
| 2 L on DOC | 0.66 (SE, 0.04) (95% CI, 0.58–0.74) |
|||||
| Chevalier 2013c [38] Advanced/metastatic NSCLC |
2 L PF | 0.70 (0.22) | EQ-5D | French (TTO) | Stage I–Stage III/IV PF and PD | Meets HAS requirements |
| 2 L PD | 0.55 (0.35) | |||||
| Chouaid 2013 [39] Advanced/metastatic NSCLC |
2 L PF | 0.74 (0.18) (95% CI, 0.68–0.80) |
EQ-5D-3 L | UK | At time of advanced diagnosis, mean age 64.8 years Adenocarcinoma: 65.2% Large-cell carcinoma: 6.8% SQ cell carcinoma: 17.1% Other: 9.9% Clinical stage at time of survey: IIIb: 17.9% IV: 82.1% |
Meets NICE requirements |
| 65.0 (19.6) (95% CI, 59.2–70.8) |
EQ-5D VAS | N/A | No | |||
| 2 L PD | 0.59 (0.34) (95% CI, 0.42–0.77) |
EQ-5D-3 L | UK | Meets NICE requirements | ||
| 53.5 (23.3) (95% CI, 41.5–65.4) |
EQ-5D VAS | N/A | No | |||
| Huang 2016c [45] Advanced PD-L1+ NSCLC |
2 L PF | 0.76 (95% CI, 0.75–0.77) | EQ-5D | NR | Multinational patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapy | Unclear as tariff NR |
| 2 L PD | 0.69 (95% CI, 0.66–0.71) | |||||
| Advanced PD-L1+ NSCLC, 2 L, > 360 days from death | 0.81 (0.79, 0.83) | Patients with advanced NSCLC and PD-L1+ tumours in 2 L on PEMB or DOC, after platinum-based chemotherapy | ||||
| Advanced PD-L1+ NSCLC, 2 L, 180–360 days from death | 0.73 (0.71, 0.75) | |||||
| Advanced PD-L1+ NSCLC, 2 L, 90–180 days from death | 0.69 (0.66, 0.72) | |||||
| Advanced PD-L1+ NSCLC, 2 L, 30–90 days from death | 0.60 (0.56, 0.64) | |||||
| Advanced PD-L1+ NSCLC, 2 L, < 30 days from death | 0.40 (0.31, 0.48) | |||||
| Iyer 2013 [46] Advanced/metastatic NSCLC |
On treatment: 2 L only | 0.53 (0.38) | EQ-5D | UK | French and German patients | Meets NICE and SMC requirements |
| 54.9 (19.3) | EQ-5D VAS | N/A | No | |||
| Langley 2013 [48] Stage IV NSCLC with brain metastases |
NSCLC with BM, previous tx allowed, OSC + WBRT 0 days | 0.63 | EQ-5D | NRd | UK and Australian NSCLC patients with brain metastases | No, as VAS tariff used |
| NSCLC with BM, previous tx allowed, OSC + WBRT 28 days | 0.49 | |||||
| NSCLC with BM, previous tx allowed, OSC + WBRT 56 days | 0.39 | |||||
| NSCLC with BM, previous tx allowed, OSC + WBRT 112 days | 0.36 | |||||
| NSCLC with BM, previous tx allowed, OSC + WBRT 168 days | 0.16 | |||||
| NSCLC with BM, previous tx allowed, OSC alone 0 days | 0.60 | |||||
| NSCLC with BM, previous tx allowed, OSC alone 28 days | 0.49 | |||||
| NSCLC with BM, previous tx allowed, OSC alone 56 days | 0.44 | |||||
| NSCLC with BM, previous tx allowed, OSC alone 112 days | 0.38 | |||||
| NSCLC with BM, previous tx allowed, OSC alone 168 days | 0.36 | |||||
| Lloyd 2008 [59] Cancer with chemotherapy-related anaemia or fatigue |
Anaemia, Hb level, ≥12.0 g/dL | 0.708 (95% CI, 0.057) | SG | N/A | General public sample from UK | No |
| 0.611 (95% CI, 0.112) | TTO | UK cancer patients who have recently experienced chemotherapy-related fatigue and anaemia completing vignette-based TTO | Meets NICE/SMC requirements but still vignette-based health state rather than patient rating own health | |||
| Nafees 2008 [59] mNSCLC |
2 L Stable diseasee | 0.65 (SE, 0.02) | SG | N/A | 100 members of general public in UK | No, but used in multiple HTA submissions |
| 2 L Responding diseasef | 0.67 | |||||
| 2 L Response gain | 0.02 (SE, 0.01) | |||||
| 2 L Progressive diseaseg | 0.47 | |||||
| Novello 2015 [49] Stage III/IV recurrent NSCLC (SQ and NSQ)h |
2 L NIN + DOC, before treatment (week 0) | 0.72 | EQ-5D | UK | Multinational patients with stage III/IV recurrent NSCLC (SQ and NSQ) in 2 L after chemotherapy Adenocarcinoma: 50.1% |
Meets NICE/SMC requirements |
| 2 L NIN + DOC, after treatment (week 30) | 0.61 | |||||
| 2 L PLA + DOC, before treatment (week 0) | 0.72 | |||||
| 2 L PLA + DOC, after treatment (week 30) | 0.62 | |||||
| 2 L NIN + DOC, before treatment (week 0) | 69.0 | EQ-5D VAS | N/A | No | ||
| 2 L NIN + DOC, after treatment (week 30) | 63.2 | |||||
| 2 L PLA + DOC, before treatment (week 0) | 69.0 | |||||
| 2 L PLA + DOC, after treatment (week 30) | 63.1 | |||||
| Reck 2015 [50] Advanced SQ NSCLC |
2 L NIVO at BL | 0.68 (0.208) | EQ-5D | NR | Multinational patients with advanced SQ NSCLC | Unclear as tariff NR |
| 2 L DOC at BL | 0.66 (0.284) | |||||
| 2 L NIVO at BL | 63.7 (18.2) | EQ-5D VAS | N/A | No | ||
| 2 L DOC at BL | 66.3 (20.5) | |||||
| Rudell 2016c [57] Advanced NSCLC, EGFR+ |
2 L OSI at BL | 65.2 (20.33) | EQ-5D-5 L VAS | N/A | Multinational patients with EGFR+ advanced NSCLC, 2 L after previous TKI | No |
| 2 L OSI at 36 weeks | 73.7 (17.33) | |||||
| Schuette 2012 [51] NSCLC Stage IIIB–IV |
2 L, PEM at BL | 0.66 (0.256) | EQ-5D | UK TTO | Austrian and German advanced/mNSCLC 2 L patients mainly after prior platinum treatment (IIIa, 6.7%; IIIb, 19.8%; IV, 73.5%) |
Meets NICE/SMC requirements |
| 2 L, PEM at 6 weeks (2nd cycle) | 0.02 (0.214) | EQ-5D gain | ||||
| 2 L, PEM at 6th cycle | 0.11 (0.228) | |||||
| 2 L, PEM at BL | 59.3 (17.8) | EQ-5D VAS | N/A | No | ||
| 2 L, PEM at 6 weeks (2nd cycle) | 3.3 (12.58) | EQ-5D VAS gain | N/A | |||
| 2 L, PEM at 6th cycle | 12.8 (17.62) | |||||
| Vargas 2009c [72] Advanced NSCLC |
2 L, on ERL | 0.81 | Global QoL index | NR | Patients with advanced NSCLC, 2 L after previous chemotherapy | No |
| 2 L, on taxanes | 0.62 | |||||
| ≥ 2nd line | ||||||
| Chen 2010c [73] Advanced NSCLCd |
2 L, DOC, during treatment | 0.45i | SG | N/A | UK general public (as algorithm based on Nafees 2008 data used to calculate utilities) | Acceptable data for SMC |
| 2 L, DOC, after treatment | 0.57 | |||||
| 2 L, PEM, during treatment | 0.54 | |||||
| 2 L, PEM, after treatment | 0.59 | |||||
| 3 L, ERL, during treatment | 0.48 | |||||
| BSC, during treatment | 0.47 | |||||
| Chevalier 2013 [38] Advanced/metastatic NSCLC |
3/4 L PF | 0.61 (0.3) | EQ-5D | French (TTO) | Stage I–Stage III/IV PF and PD | Meets HAS requirements |
| 3/4 L PD | 0.42 (0.40) | |||||
| Griebsch 2014 [37] Stage IIIb (with pleural effusion)/IV NSCLC adenocarcinoma (LUX-LUNG 1)j |
Week 4, progression effect longitudinal model | −0.1 | EQ-5D | UK | Multinational advanced/metastatic NSCLC, 2 LL | Meets NICE requirements |
| Mixed effect longitudinal model IRC | −0.056 (95% CI, − 0.083 to − 0.028) |
|||||
| Mixed effect longitudinal model IN | −0.065 (95% CI, − 0.092 to − 0.039) |
|||||
| Mixed effect longitudinal model IRC, AFA | −0.06 | |||||
| Mixed effect longitudinal model IRC, BSC | −0.046 | |||||
| Mixed effect longitudinal model IINV, AFA | −0.081 | |||||
| Mixed effect longitudinal model IINV, BSC | −0.033 | |||||
| Week 4, progression effect longitudinal model | −7.3 | EQ-5D VAS | N/A | No | ||
| Mixed effect longitudinal model IRC | −3.76 (95% CI, −5.19 to −2.32) | |||||
| Mixed effect longitudinal model INV | − 3.83 (95% CI, − 5.21 to − 2.44) | |||||
| Mixed effect longitudinal model IRC, AFA | 3.63 | |||||
| Mixed effect longitudinal model IRC, BSC | −4.11 | |||||
| Mixed effect longitudinal model INV, AFA | −4.42 | |||||
| Mixed effect longitudinal model INV, BSC | −2.55 | |||||
| Hirsh 2013 [40] Stage IIIB/IV NSCLC |
3 LL on AFA + BSC | 0.71 | EQ-5D | UK | 98% adenocarcinoma PD following treatment lines 1–2, one of which was platinum based, plus PD after at least 12 weeks of ERL or GEF |
Meets NICE requirements |
| 3 LL on PLA + BSC | 0.67 | |||||
| 3 LL on AFA + BSC | 67.4 | EQ-5D VAS | N/A | No | ||
| 3 LL on PLA + BSC | 65.2 | |||||
| Schwartzbergc 2015 [60] Stage IIIb/IV NSCLC (SQ & NSQ) |
All patients wk 6 | 1.0 (21.7) | EQ-5D VAS | N/A | Patients, 2 LL, NIVO 3 mg/kg i.v. q2w | No |
| wk 12 | 5.8 (21.3) | |||||
| wk 18 | 8.2 (22.3) | |||||
| wk 24 | 8.2 (23.9) | |||||
| wk 30 | 8.4 (29.2) | |||||
| SDis wk 6 | 3.8 (19.8) | |||||
| wk 12 | 6.4 (21.9) | |||||
| wk 18 | 8.2 (20.9) | |||||
| wk 24 | 5.2(21.9) | |||||
| wk 30 | 7.2 (28.5) | |||||
| PR wk 6 | 7.3 (22.4) | |||||
| wk 12 | 6.6 (24.7) | |||||
| wk 18 | 8.1 (27.6) | |||||
| wk 24 | 18.1 (31.0) | |||||
| wk 30 | 13.7 (38.2) | |||||
| PD wk 6 | −5.8 (21.1) | |||||
| wk 12 | −3.0 (19.8) | |||||
| wk 18 | 3.9 (24.3) | |||||
| wk 24 | 6.8 (12.2) | |||||
| wk 30 | 5.5 (15.7) | |||||
| Treatment line not specified | ||||||
| Bradbury 2008c [42] Advanced NSCLC |
On ERL | 0.772 | EQ-5D | NR (possibly Canadian) | Canadian patients | Potentially relevant to CADTH |
| On BSC | 0.754 | |||||
| Chang 2016c [63] Advanced NSCLC |
> 360 days from death | 0.904 (95% CI, 0.892–0.917) |
TTO | NR | General public, South Korea | No |
| 180–360 days from death | 0.720 (95% CI, 0.692–0.748) |
|||||
| 90–180 days from death | 0.627 (95% CI, 0.598–0.655) |
|||||
| 30–90 days from death | 0.379 (95% CI, 0.349–0.409) |
|||||
| < 30 days from death | 0.195 (95% CI, 0.172–0.218) |
|||||
| Dansk 2016c [43] Advanced NSCLC |
Synthesized PF | Median, 0.706 Range, 0.620–0.815 |
Synthesized utility across > 1 instrument type | NR | Utilities synthesized included those where respondents were patients and those where they were the general public considering a hypothetical health state | No |
| Synthesized PF trial-based | Median, 0.750 Range, 0.627–0.815 |
|||||
| Synthesized PF non-trial-based | Median, 0.653 Range, 0.620–0.653 |
|||||
| Synthesized PD | Median, 0.565 Range, 0.470–0.688 |
|||||
| Synthesized PD trial-based | Median, 0.599 Range, 0.550–0.688 |
|||||
| Synthesized PD non-trial-based | Median, 0.473 Range, 0.470–0.530 |
|||||
| Doyle 2008 [65] Metastatic NSCLC |
SDis, no additional symptoms | 0.626 | SG | N/A | General public | No |
| Treatment response, no additional symptoms | 0.712 | |||||
| Grunberg 2009c [58] BC/LC |
Chemotherapy-induced nausea and vomiting of differing severity | Reported graphically | SG | N/A | Patients BC/LC | Meets NICE requirements |
| Grutters 2010c [44] NSCLC (stage unspecified) |
NSCLC with grade 3+ dyspnoea, stage unspecified | Median, 0.52 | EQ-5D-5 L | NR | Patients at an early treatment stage | No |
| Jang 2010 [47] Stage IV NSCLC |
Stage IV NSCLC | 0.75 (0.15) | EQ-5D | US | Patients with NSCLC attending a major Canadian cancer center outpatient clinic | No |
| Linnet 2015c [62] Stage IV NSCLC on oral VINO |
PCS, cycle 2 | 37.0 | SF-12 | N/A | Patients | No |
| PCS, cycle 3 | 38.6 | |||||
| MCS, cycle 2 | 47.7 | |||||
| MCS, cycle 3 | 44.2 | |||||
| PCS, cycle 2 | 52.9 | Caregivers | Potential to estimate SF-6D for caregivers to mNSCLC patients, for SMC or CADTH | |||
| PCS, cycle 3 | 53.4 | |||||
| MCS, cycle 2 | 46.2 | |||||
| MCS, cycle 3 | 44.6 | |||||
| Lloyd 2005c [66] Stage IV NSCLC |
RES | 0.70 | SGk | N/A | General public | No |
| SDis, oral treatment | 0.63 | |||||
| SDis, i.v. treatment | 0.58 | |||||
| PD | 0.42 | |||||
| End of life | 0.33 | |||||
| Manser 2006 [61] Stage IV NSCLC |
Stage IV | Median, 0.68 (IQR, 0.54–0.82) |
AQoL | Australia | Mixed stage enrolled: I, 31.5%; II, 17.4%; IIIa, 16.3%; IIIb, 7.6%; IV, 25.0% |
No |
| Matza 2014 [67] Stage IV cancer with bone metastases |
Cancer with bone metastases and no SRE | 0.47 (0.41) | TTO | N/A | General public, UK (Edinburgh and London) |
No |
| 0.47 (0.45) | General public, Canada (Montreal and Toronto) |
|||||
| 0.47 (0.42) | General public, UK and Canada | |||||
| Stewart 2015 [56] EGFR+ Stage IV NSCLC |
PR/SDis on EGFR TKIs (GEF, ERL, AZD9291) | 0.82 (SE, 0.16) | EQ-5D-3 L | NR | Patients, eligible for or on TKI tx, 55% Asian, 45% male, median age 60, 66% never smokers. Stage IV: at diagnosis, 80% when surveyed, 100% |
Unclear |
| Responded to standard chemotherapy | 0.80 (SE, 0.12) | |||||
| EGFR+, responded to GEF | 0.84 (SE, 0.14) | |||||
| EGFR+, responded to ERL | 0.82 (SE, 0.17) | |||||
| EGFR+, responded to AZD9291 | 0.83 (SE, 0.16) | |||||
| EGFR+, PD during TKI treatment (GEF, ERL, AZD9291) | 0.74 (SE, 0.08) | |||||
| EGFR+, all patients (PR/SDis/PD), 25% 3LL | 0.802 | |||||
| Tabberer 2006 [52] Advanced NSCLC |
RES | 0.49 | EQ-5D | NR | General public, UK (Cardiff, Glasgow, London and Oxford) |
No |
| SDis | 0.46 | |||||
| SDis + oral treatment | 0.45 | |||||
| SDis + i.v. treatment | 0.43 | |||||
| PD | 0.22 | |||||
| Near death | 0.15 | |||||
| Trippoli 2001 [53] Metastatic NSCLC |
Metastatic NSCLC | 0.53 (0.36) | EQ-5D | UK (TTO) | Italian patients | Meets NICE and SMC reference cases |
| 0.55 (0.22)l | EQ-5D VAS | N/A | No | |||
| Yang 2014 [54] Stage IIIB/IV NSCLC |
Stage IV inoperable, performance status 0–1 | 0.75 (0.22) | EQ-5D | Taiwan | Patients, mixed NSCLC stages: I, 0.8%; II, 0%; IIIA, 4.5%; IIIB, 16.9%; IV, 77.8% | No |
| Stage IV inoperable, performance status 0–4 | 0.75 (0.22) | |||||
| Yokoyama 2013c [55] Advanced NSCLC/SCLC |
Stage IIIB/IV NSCLC/SCLC with bone metastasis and SRE | NR | EQ-5D | NR | Patients, advanced NSCLC, 72%, SCLC, 28% NSCLC and SCLC: IIIB, 37%; IV, 63% |
No |
aMean, or mean (SD) unless stated otherwise
bVAS scores were also reported in this study but unclear whether this was EQ-VAS
cThese studies were published as abstracts or posters
dThis referenced article (https://www.ncbi.nlm.nih.gov/pubmed/10109801) is for a VAS valuation
e SDis vignette:
• You have a life-threatening illness that is stable on treatment. You are receiving cycles of treatment that require you to go to the outpatient clinic
• You have lost weight, and your appetite is reduced. You sometimes experience pain or discomfort in your chest or under your ribs, which can be treated with painkillers. You have shortness of breath, and breathing can be painful. You have a persistent nagging cough
• You are able to wash and dress yourself and do jobs around the home. Shopping and daily activities take more effort than usual
• You are able to visit family and friends but often have to cut it short because you get tired
• You sometimes feel less physically attractive than you used to. Your illness has affected your sex drive
• You worry about dying and how your loved ones will cope
f Second-line responding vignette:
• You have a life-threatening illness that is responding to treatment. You are receiving cycles of treatment which require you to go to the outpatient clinic
• You are gaining back your weight and your appetite is returning. You occasionally experience pain or discomfort in your chest or under your ribs which can be treated with painkillers. You sometimes have shortness of breath. You occasionally have a nagging cough
• You are able to wash and dress yourself and do jobs around the home. Shopping and daily activities can sometimes be tiring
• You are able to visit family and friends but sometimes have to cut it short because you get tired
• You occasionally feel less physically attractive than you used to. Your illness has somewhat affected your sex drive
• You sometimes worry about dying and how your loved ones will cope
g Second-line PD vignette:
• You have a life-threatening illness, and your condition is getting worse
• You have lost your appetite and have experienced significant weight loss. You experience pain and discomfort in your chest or under your ribs. You frequently have shortness of breath, and breathing is often painful. You have a persistent nagging cough and sometimes cough up blood. You may experience some difficulty swallowing
• You experience severe fatigue and feel too tired to go out or to see family and friends. It has affected your relationships with them
• You need assistance to wash and dress yourself. You are often unable to do jobs around the house or other daily activities. You are dependent on others to do your shopping and are unable to do your usual daily activities
• You often feel less physically attractive than you used to. You have little or no sexual drive
• You are depressed, and dying is always on your mind. You worry about how your loved ones will cope
hThis study also has utilities available every 3 weeks between week 0 and week 30 for all treatments
iAll utilities in this paper assumed to be the mean, although it is not clearly stated in the paper
j1 L data also reported from LUX-LUNG 3
kIndividual country values are also available in this publication
lThis value is reported as in the original publication
Abbreviations: 1 L first line, 2 L second line, 2 LL second and subsequent line, 3 LL third and subsequent line, AFA afatinib, ALK+ anaplastic lymphoma kinase mutation positive, AQoL Assessment of Quality of Life instrument, BC breast cancer, BL baseline, BSC best supportive care, CADTH Canadian Agency for Drugs and Technologies in Health, CI confidence interval, CRZ crizotinib, DOC docetaxel, EGFR epidermal growth factor receptor, EGFR+ epidermal growth factor receptor mutation positive, EORTC QLQ European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire, EQ-VAS EuroQol visual analogue scale, ERL erlotinib, GEF gefitinib, HAS Haute Autorité de Santé, HTA health technology assessment, IQR interquartile range, i.v. intravenous, LC lung cancer, MCS mental component summary, mNSCLC metastatic non-small cell lung cancer, N/A not applicable, NICE National Institute for Health and Care Excellence, NIN nintedanib, NIVO nivolumab, NR not reported, NSCLC non-small cell lung cancer, NSQ non-squamous, NTS not treatment-specific, OSC optimal standard care, OSI osimertinib, PCS physical component summary, PD progressive disease, PEM pemetrexed, PF progression-free, PLA placebo, PR partial response, PSS progression-status specific, q2w once every 2 weeks, QoL quality of life, RES response, SCLC small-cell lung cancer, SD standard deviation, SDis stable disease, SE standard error, SF-6D 6-dimension Short-Form Health Survey, SF-12/36 12-/36-item Short-Form Health Survey, SG standard gamble, SMC Scottish Medicines Consortium, SQ squamous, SRE skeletal-related event, TKI tyrosine kinase inhibitor, TTO time trade-off, VAS visual analogue scale, VINO vinorelbine, WBRT whole-brain radiotherapy